RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
  Adrenergics
  Analgesics
  Anti Cancer Drugs
  Anti-Clotting Drugs
  Anti-Inflammatory
  Antibiotics
  Anticholesterol
  Antihypertensives
  Antivirals
  Fatty Acids
  Hypnotics
  Metals
  PPI
  Surfactants
  Varenicline
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Pharmacology Channel

subscribe to Pharmacology newsletter
Latest Research : Pharmacology

   EMAIL   |   PRINT
FDA Approves High Dose Kadian(R) for Severe Chronic Pain

May 6, 2005 - 10:13:00 AM
"Kadian(R) already has a significant advantage over competitive products as a result of the dosing flexibility it offers physicians and their patients and is the only brand in its category that can be dosed either once or twice daily. This added dosage form, which will be marketed by our recently expanded sales force, will help physicians individualize their patients treatments by offering more choices in managing their pain."

 
[RxPG] Alpharma Inc. (NYSE: ALO),a leading global generic pharmaceutical company, today announced that it has been notified by United States Food and Drug Administration that its pending application for Kadian(R) 200mg capsule has received approvable status.

Kadian(R) is Alpharma's branded sustained release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages. The company plans to launch the new dosage form following final FDA approval.

"We are extremely pleased to receive approvable status on this important new higher dosage of Kadian(R) which will help meet the needs of some the most severe sufferers of chronic pain," commented Ronald Warner, PhD, President of
Alpharma's Branded Products business. "Kadian(R) already has a significant advantage over competitive products as a result of the dosing flexibility it offers physicians and their patients and is the only brand in its category
that can be dosed either once or twice daily. This added dosage form, which will be marketed by our recently expanded sales force, will help physicians individualize their patients treatments by offering more choices in managing their pain."



Publication: U.S. Food and Drug Administration (FDA)
On the web: www.alpharma.com 

Advertise in this space for $10 per month. Contact us today.


Related Pharmacology News
Palliative radiotherapy for bone metastases in elderly patients improves quality of life
Research shows promise for microwave ablation to relieve painful bone and soft-tissue tumors
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study suggests dexmedetomidine before surgery reduced remifentanil-induced hyperalgesia
Research examines effects of opioids on patients with sickle cell disease
Full range of treatment settings and their effects on radiofrequency heat lesion size
High-dose opioids disturb hormones long-term, but mental and physiologic function improves
Web-based tools found to enhance recruitment and prescreening for clinical pain trials
Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain
Study: Pain improves during first year but mental-health problems linger

Subscribe to Pharmacology Newsletter

Enter your email address:


 Additional information about the news article
Alpharma Inc. (NYSE: ALO) is a global generic pharmaceutical company with leadership positions in products for humans and animals. Uniquely positioned to expand internationally, Alpharma is presently active in more than 60 countries. Alpharma is a leading manufacturer of generic pharmaceutical products in the U.S., offering solid, liquid and topical pharmaceuticals. It is also one of the largest suppliers of generic solid dose pharmaceuticals in Europe, with a growing presence in Southeast Asia. Alpharma is among the worlds leading producers of several important pharmaceutical-grade bulk
antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry, swine and cattle.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)